Drug intelligence / Profile preview

TLG-FT19

Development stage: Preclinical
Lead developer: Porosome Therapeutics
Modality: Nanoparticles → Drug Delivery Systems

Overview

TLG-FT19 is an investigational porosome nanoparticle therapy being developed by Porosome Therapeutics for the treatment of various tumors. The therapy utilizes the company's proprietary porosome-based delivery platform. Porosomes are cup-shaped lipoprotein structures that serve as the universal secretory portals in cells, facilitating the precision release of cellular contents. By leveraging these natural secretory pathways, TLG-FT19 is designed to deliver therapeutic payloads directly to tumor cells with high specificity, potentially enhancing efficacy while reducing systemic side effects. The drug is currently in mid-stage development for oncological indications.

Targets

porosome (Porosome-associated protein complex)

Beyond the preview

Go deeper on TLG-FT19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TLG-FT19.

Explore the full profile